United Neuroscience announces results from Phase II study of UB-311 vaccine in people with AD


On 16 January, United Neuroscience, a clinical-stage biotechnology company developing active immunotherapeutics to treat and prevent brain disorders, announced top-line results of its Phase IIa trial of UB-311 vaccine in people with Alzheimer’s disease (AD). The Phase IIa was a randomised, double blind and placebo-controlled study evaluating the safety, efficacy and immunogenicity of UB-311, the novel synthetic peptide vaccine targeting Aβ peptides, in people with AD.

UB-311 vaccine was well tolerated and the trial met the primary outcomes measures of safety and immunogenicity with a 96% response rate. Although improvements on all secondary measures – including changes in Amyloid burden, cognition, global assessment and behavioural assessment- were observed, they were not statistically significant. The company expects to present additional results at upcoming meetings such as the 14th International Conference on Alzheimer's and Parkinson's Diseases (Lisbon, March 2019).